Double Bond Pharma signs logistics agreement with Tamro

Today, Double Bond Pharmaceutical has signed an agreement with the wholesaler Tamro for distribution and storage of its product Pileseptin in Sweden, Norway and Denmark. Tamro is Sweden’s only independent pharmaceutical logistics service provider and is known to have both the world-class knowledge and experience in this type of services. Pileseptin, a product that Double Bond signed a distribution agreement for in December 2017, is an innovative formulation that strengthens the healing effect of hemorrhoids, and is part of Double Bond’s venture into drug distribution through its subsidiary Drugsson.

“It’s an important developmental step that Drugsson takes within this agreement with Tamro”, commented Igor Lokot, CEO of Double Bond. “We aim at having Double Bond, through Drugsson’s revenue alone, to become a self-sufficient enterprise by 2019”.

More about Tamro

This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 26 April 2018.

Contact information

Full Company Name:  

Double Bond Pharmaceutical International AB (publ)

Corporate identity:      


Stock short name:      


Share ISIN code:        


For more info, contact
Igor Lokot, CEO




Follow us on:

LinkedIn, Facebook and Twitter

Information on Double Bond Pharmaceutical International AB

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.

Share this post